CD19 and systemic lupus erythematosus: hAAT gene therapy increased the percentage of CD19+ B cells in the spleen (Figure 5G), while it did not affect the frequency of class-switched B cells or germinal center class-switched B cells (data not shown), which are B cell subsets that are expanded in lupus and normally associated with anti-dsDNA IgG production.